NCT00480246View on ClinicalTrials.gov

A Positron Emission Tomography (PET) Study to Assess the Degree of Dopamine-2 (D2) Receptor Occupancy in the Human Brain After Single Doses of BL-1020 or Perphenazine in Healthy Male Subjects Using [11C]Raclopride as PET Tracer

PHASE1CompletedINTERVENTIONAL

Timeline

Start Date

May 31, 2007

Conditions

Healthy

Interventions

DRUG

BL 1020

DRUG

Perphenazine

Trial Locations (1)

Unknown

Quintiles Phase I facility, Uppsala

Sponsors

Lead Sponsor

BioLineRx, Ltd.

All Listed Sponsors

lead

BioLineRx, Ltd.

INDUSTRY

NCT00480246 - A Positron Emission Tomography (PET) Study to Assess the Degree of Dopamine-2 (D2) Receptor Occupancy in the Human Brain After Single Doses of BL-1020 or Perphenazine in Healthy Male Subjects Using [11C]Raclopride as PET Tracer | Biotech Hunter | Biotech Hunter